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Off-target mechanismDrugsmay induce adverse drug reactions (ADRs)when they unexpectedly bind to proteins other than their ther-
apeutic targets. Identiﬁcation of these undesired protein binding partners, called off-targets, can facilitate toxicity
assessment in the early stages of drug development. In this study, a computational framework was introduced
for the exploration of idiosyncratic mechanisms underlying analgesic-induced severe adverse drug reactions
(SADRs). The putative analgesic-target interactions were predicted by performing reverse docking of analgesics
or their active metabolites against human/mammal protein structures in a high-throughput manner. Subse-
quently, bioinformatics analyses were undertaken to identify ADR-associated proteins (ADRAPs) and pathways.
Using the pathways and ADRAPs that this analysis identiﬁed, themechanisms of SADRs such as cardiac disorders
were explored. For instance, 53 putative ADRAPs and 24 pathways were linked with cardiac disorders, of which
10 ADRAPs were conﬁrmed by previous experiments. Moreover, it was inferred that pathways such as base ex-
cision repair, glycolysis/glyconeogenesis, ErbB signaling, calcium signaling, and phosphatidyl inositol signaling
likely play pivotal roles in drug-induced cardiac disorders. In conclusion, our framework offers an opportunity
to globally understand SADRs at the molecular level, which has been difﬁcult to realize through experiments. It
also provides some valuable clues for drug repurposing.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Adverse drug reactions (ADRs) are unexpected effects that occur
during normal chemotherapy. Severe ADRs (SADRs) are normally char-
acterized as requiring hospitalization, prolonging hospitalization, being
permanently disabling or fatal (Wilke et al., 2007). According to recent
statistics in the “Reports Received and Reports Entered into FAERS by
Year” from the Food andDrugAdministration (FDA) of USA, the number
of reported ADRs increased more than 10% every year from 2005 to
2011 (US FDA, 2011). Another report indicated that serious adverse
drug events increased 2.6-fold from 1998 through 2005 and that fetal
adverse drug events increased 2.7-fold (Moore et al., 2007). It was esti-
mated that SADRs may cost nearly as much as the drug treatment itself
(Ingelman-Sundberg, 2008). SADRs are also one of the major factors
that lead to drug development failure. To maximally avoid undesired
SADRs, a number of experimental assays and computational toxicologyDRs, severe adverse drug reac-
s, lung disorders.
ress Cell Biology, School of Life
hina. Fax: +86 0592 2182897.
. Open access under CC BY license.tools have been adopted in early drug discovery stages to ﬁlter out can-
didates with the high potential for ADRs from drug candidate pools
(Bender et al., 2007; Kwan et al., 2006; Muster et al., 2008). Unfortu-
nately, many of these toxicity analyses did not result in rules or empir-
ical knowledge that can be reused for further drug safety evaluation.
This weakness was caused by poor understanding of the mechanisms
underlying SADRs.
The causes of ADRs are complex and vary by case. To summarize,
drugs may induce adverse reactions through any combination of the
following four broad areas: change of micro-environment (Muster
et al., 2008; Valerio, 2009), ligand-receptor interaction (on-target or
off-target) (Bender et al., 2007; Liebler and Guengerich, 2005), gene
regulation and immunemediation (Ji et al., 2003). Although the general
mechanisms by which a drug induces ADRs have been summarized,
exact knowledge of how a particular ADR is induced remains unclear.
Investigation of a drug-target proﬁle is an efﬁcient approach to solv-
ing various problems in etiology and pharmacology (Lindsay, 2003). For
instance, the therapeutic effects of a drug generally result from the inter-
action of the drug with one or more proteins or nucleic acids (so-called
therapeutic targets) that are critical in disease processes. Likewise, ad-
verse reactions to a drug are often induced by undesired interactions of
the drug with crucial proteins (off-targets) within physiological path-
ways other than its therapeutic target(s). Hence, the acquisition of a
complete drug-off-target interaction proﬁle can potentially facilitate bet-
ter understanding of molecular mechanisms underlying ADRs. However,
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nologies to determine what proteins are involved and, furthermore,
how the SADRs are triggered and boosted via protein interaction
networks. The recent development of toxicogenomics, adopting high
throughput technologies such as gene microarrays, enables researchers
to monitor the expression of thousands of genes and proteins simulta-
neously to detect ADR-associated genes or proteins. Even so, it is still dif-
ﬁcult to address these questions because of the difﬁculty of obtaining
enough experimental samples, the high cost and the difﬁculty of data
analysis. Therefore, in this study, a computational framework was intro-
duced to rapidly identify putative off-targets of drugs in a high-
throughput manner. Upon these off-targets, the idiosyncratic mecha-
nisms underlying SADRs were investigated in a way of molecular
network.
Methods
The computational framework. The framework is composed of four se-
quential analyses. First, the putative protein targets of analgesics were
predicted by simulation of drug–target interactions in a large scale using
docking software. This step generated the binding target proﬁles for an-
algesics. Second, the common off-targets were determined for the se-
lected SADRs by overlapping the target proﬁles of analgesics that were
reported to induce the SADRs. It was assumed that the common off-
targets of selected analgesics may partially answer for their common
idiosyncratic SADRs. Third, ADR-pathway associations were built by
integrating literature-reported drug-ADR, protein–ADR, and protein–
pathway relations. The ADR–pathway association networks were also
constructed. Fourth, the putative SADR-associated proteinswere identi-
ﬁed for the selected SADRs by mapping the common off-targets against
the corresponding SADR–pathway association sub-networks. Upon the
putative SADR-associated proteins andpathways, diagramswere drawn
for better illustration of SADR mechanisms.
Analgesic drugs and their active metabolites. In this study, six commonly
marketed analgesic drugs, which were most frequently reported in
fatal and nonfatal serious events (Moore et al., 2007), were chosen
for a mechanistic study. They are oxycodone, fentanyl, morphine,
acetaminophen, liquicet (acetaminophen–hydrocodone), and rofecoxib
(withdrawn from the market). Their pharmacological properties
and molecular structures were derived from the DrugBank database
(http://www.drugbank.ca) (Knox et al., 2011). These characteristics
were brieﬂy summarized in Table 1.
The pharmacokinetic processes (or ADME) have a direct inﬂuence
on drug efﬁcacy and toxicity. For example, oxycodone can be extensive-
lymetabolized to noroxycodone, oxymorphone, and their glucuronides.
Both noroxycodone and oxymorphonewere reported to exhibit analge-
sic activity (Knox et al., 2011). Therefore, not only the drug itself but also
its major active metabolites were considered in the ADR mechanism
study. The active metabolites of these six analgesics was collected
from literatures and listed in Table 1. As the combinatorial analgesic
liquicet is metabolized separately in the human body, its toxicity was
evaluated by combining independent analyses of acetaminophen and
hydrocodone.
Selection of severe adverse drug reactions. The ADR information for the
analgesic drugs was mainly derived from the DailyMed database
(http://dailymed.nlm.nih.gov/dailymed/) as well as the literature.
DailyMed is a public database that provides standard, comprehensive
and up-to-date FDA-labeled drug information, including adverse reac-
tions and pharmacokinetics. By August 2013, it contains more than
50,000 drugs. The ADR terms of analgesics were standardized before
later analyses. In total, 65 distinct ADRs were reported for these six anal-
gesics. Some of them are common to analgesics and potentially fatal, e.g.,
cardiac disorders. Some are drug-speciﬁc, e.g., oxycodone-induced lung
disorders. Partial list of the SADRs was given in Supplementary Table 1S.In thiswork, only three severe ADRs, cardiac disorders (CDs), cardiac
arrhythmias (CAs) and lung disorders (LDs) were selected as represen-
tatives for mechanism study under the considerations of: These three
ADRs are of general interests, however, severe and sometimes fatal. Of
the three SADRs, CDs were reported in all six analgesics treatment; to
the contrast, LDs were oxycodone-speciﬁc. CAs were included as a sub-
set of CDs and two analgesics (oxycodone and fentanyl) were involved.
The selection of these three SADRs represents different situations of
drug–SADR relations, which will help to evaluate the performance of
the computational framework.
Identiﬁcation of putative analgesic–target interactions. The putative pro-
tein targets of a drug (and itsmetabolites)were identiﬁed by simulation
of ligand–receptor interaction using the reverse docking software
INVDOCK (Chen and Ung, 2002). INVDOCK is a ligand–protein inverse
docking algorithm,which conducts a computer-automated search of po-
tential protein targets of a small molecule by attempting to dock it to a
cavity of each of these proteins. The target search was carried out in
the pool of human and mammal protein structures available in the
Protein Structure Bank (PDB) (http://www.rcsb.org) by September
2012 (Rose et al., 2013). The putative protein targets were determined
in basis of a scoring schemewhich performed competitive binding anal-
ysis in addition to the evaluation of molecular mechanics ligand–protein
interaction energy (Chen and Zhi, 2001). An empirical threshold score of
smaller than −20 was adopted for positive assignment of drug–target
interactions. To deal with the redundancy of PDB structures, all docked
proteinsweremapped to their human homologs, and only one represen-
tative remained. The putative drug–target interactions were further vali-
dated by seeking experimental evidences in public databases like
BindingDB and ChEMBL. The BindingDB (http://www.bindingdb.org/
bind/index.jsp) is a free database of measured bindingn afﬁnities of
ligand–protein interactions (Liu et al., 2007). Currently, BindingDB con-
tains more than 1 million binding data for 6910 protein targets and
421,849 small molecules. ChEMBL (https://www.ebi.ac.uk/chembl/) is
a manually curated database for drug-like ligands and their activities
(Gaulton et al., 2012). Its latest version 17 contains comprehensive in-
formation of more than 9000 targets and 1million compounds derived
from the literature.
Determination of common off-targets. The putative off-targets for each
analgesic drug were determined by removing the known therapeutic
targets from the corresponding non-redundant docking protein list.
The combinatorial analgesic drug liquicet was analyzed by its two com-
ponents, acetaminophen and hydrocodone, separately. The common
off-targets for a designated SADR were determined by seeking the over-
lapped off-targets of analgesics according to their commonality in induc-
tion of the SADR.
Identiﬁcation of ADR-associated pathways. The ADR-associated proteins
(ADRAPs) are proteins that likely mediate ADRs via their binding to
drugs or xenobiotics. The literature-reported ADRAPs were derived
from the Drug-Induced Toxicity Related Proteins Database (DITOP,
http://bioinf.xmu.edu.cn/databases/DITOP/index.html) (Zhang et al.,
2007) and the literature. TheDITOPdatabase currently contains 618dis-
tinct literature-reported ADRAPs, 529 drugs/ligands, and 418 distinct
toxicity terms. The ADR-associated pathways are a group of biological
pathways, dysfunction of whichmay directly induce ADRs. In this study,
the ADR-associated pathways were obtained by mapping the known
ADRAPs into the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway database (http://www.genome.jp/kegg/). Current version of
KEGG database provides a collection of 449 pathwaymaps representing
knowledge on molecular interaction and reaction networks (Kanehisa
et al., 2012).
All ADR–pathway associations obtained for the six analgesics were
integrated in a formof interaction network using the freeware Cytoscape
with the yFiles Organic Layout algorithm (Shannon et al., 2003). For a
Table 1
The general information of the six analgesics.
Drug name Active metabolites 2D structure Therapeutic targets
Acetaminophen Acetaminophen Prostaglandin G/H synthase 2 (Chen et al., 2002)
Prostaglandin G/H synthase 1 (Chen et al., 2002)
Acetimidoquinone N.A.
Fentanyl Fentanyl μ-type opioid receptor (You et al., 2005)
δ-type opioid receptor (Rodrigues et al., 2005)
κ-type opioid receptor (Pascoe et al., 2008)
Morphine Morphine μ-type opioid receptor (Yamada et al., 2006)
δ-type opioid receptor (Overington et al., 2006)
κ-type opioid receptor (Yamada et al., 2006)
Oxycodone Oxycodone μ-type opioid receptor (Ordonez Gallego et al., 2007)
δ-type opioid receptor (Ordonez Gallego et al., 2007)
κ-type opioid receptor (Ordonez Gallego et al., 2007)
Oxymorphone μ-type opioid receptor (Spetea et al., 1998)
δ-type opioid receptor (Chamberlin et al., 2007)
Rofecoxib Rofecoxib Prostaglandin G/H synthase 2 (Ehrich et al., 1999)
Elastin (Oitate et al., 2006)
Liquicet Acetaminophen Prostaglandin G/H synthase 2 (Chen et al., 2002)
Prostaglandin G/H synthase 1 (Chen et al., 2002)
Hydrocodone μ-type opioid receptor (Chen et al., 2002)
δ-type opioid receptor (Chen et al., 2002)
Hydromorphone μ-type opioid receptor (Quigley, 2002)
δ-type opioid receptor (Fang et al., 1997)
κ-type opioid receptor (Overington et al., 2006)
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Table 2
The putative targets for analgesics and their major activemetabolites predicted by reverse
docking method.
Drug name Active metabolites Target number
(by active metabolites)
Target number
(by drug)
Acetaminophen Acetaminophen 642 745
Acetimidoquinone 391
Fentanyl Fentanyl 448 448
Morphine Morphine 454 454
Oxycodone Oxycodone 412 557
Oxymorphone 487
Rofecoxib Rofecoxib 842 842
Liquicet Acetaminophen 642 821
Acetimidoquinone 391
Hydrocodone 257
Hydromorphone 400
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from the whole ADR–pathway association network.
Identiﬁcation of putative ADRAPs and construction of ADRAP–pathway
connection maps for selected SADRs. The putative ADRAPs for a designat-
ed SADR were identiﬁed by mapping the common off-targets of the
SADR into its corresponding ADR–pathway association sub-network.
Those mapped off-targets were considered as putative ADRAPs for the
selected SADR. For instance, there are 182 common off-targets for
all six analgesics. Mapping of these off-targets against the cardiac-
disorders–pathway association sub-network identiﬁed 53 putative
cardiac-disorders-associated targets.
Moreover, upon the putative ADRAPs and ADR-associated pathways,
connection maps were constructed for selected SADR (CDs, CAs and
LDs in this study) using the Cytoscape with the yFiles Circular Layout
algorithm (Shannon et al., 2003).
Assessment of ADR–pathway associations. The odds ratio (OR) was intro-
duced in this study to measure strength of ADR–pathway association
(Newman, 1988). For a pathway–SADR pair, the odds ratio was deter-
mined by Eq. (1).
Odds ratio ORð Þ ¼ Ae=Aneð Þ= Ne=Nneð Þ: ð1Þ
In Eq. (1), Ae stands for the number of SADR-associated proteins in a
designated pathway, and Ne stands for the number of remaining pro-
teins in the pathway excluding Ae; Ane stands for the total number of
SADR-associated proteins in all SADR-associated pathways, and Nne
stands for the total number of proteins in all SADR-associated pathways
excluding Ane. The higher OR value suggests the stronger association. In
this study, an OR value of equal or more than 1.5 was considered as
strong association; and at the meanwhile, an OR value of less than or
equal 0.5 was considered as weak association.
Results
The putative target proﬁles of analgesic drugs
On average, the analgesics (including theirmajor activemetabolites)
were predicted to target 500 to 1100 human/mammal PDB protein
structures. A second sequence of data processing was performed to re-
move the redundant targets from the putative target list. As a conse-
quence, the number of targets was reduced to approximately 448–842
per drug. The number of putative protein targets for six analgesics was
summarized in Table 2. The analgesic–target interactions were further
validated by experiment data. Unfortunately, due to the limitation of
public data, only a small portion (averagely, less than 5% of total interac-
tions) of drug–target interactions can be veriﬁed by experimental data.
For instance, 20 out of 642 acetaminophen–target interactions were
supported by experiments. Majority of these predicted interactions
have no experimental evidences for validation yet. However, it is wor-
thy of mention that most of the therapeutic targets of these six analge-
sicswere successfully predicted. For instance,morphine, oxycodone and
fentanyl are opioids or derivatives of opioid. They exert similar analgesic
effects through agonism of the μ-type or κ-type opioid receptors (Kalso,
2007). As shown in Table 2, 454, 557 and 448 non-redundant putative
targets were predicted for morphine, oxycodone and fentanyl, respec-
tively. The target lists included their literature-proposed therapeutic
targets, the δ-type, μ-type and κ-type opioid receptors.
Liquicet (acetaminophen–hydrocodone) is a combinational drug de-
signed for relieving patients from severe pain. It was observed to have
potent analgesic effects by enhanced inhibition of prostaglandins in an
synergistic mechanism that has not been well-studied yet (Barkin,
2001). Hydrocodone is a semi-synthetic opioid analgesic acting on
μ-opioid receptor. Its pharmacological and toxicological behaviors
are similar to those of other opioids. In total, 257 and 400 putativetargets were predicted for hydrocodone and its major active metabolite
hydromorphone respectively. Unlike opioids, acetaminophen (or
paracetamol) is an aniline analgesic member of the non-steroidal
anti-inﬂammatory drugs (NSAIDS) that is commonly used for the
management of perioperative pain. Its exact mechanism of thera-
peutic action is currently controversial. Recent research proposed
that the prostaglandin G/H synthase 2 (COX2) may be the therapeu-
tic target of acetaminophen (Hinz et al., 2008). Comparatively, acet-
aminophen is a mild painkiller, but it may increase the potential risk
for severe liver damage due to its metabolite acetimidoquinone
(James et al., 2003). In this study, acetaminophen and its active
metabolite acetimidoquinone were predicted to have 642 and 391
non-redundant putative targets, respectively. The potential therapeutic
target COX2 was on the docking lists.
Rofecoxib (marketed as Vioxx) is a NSAID that exerts analgesic ef-
fects by selectively inhibiting the COX2 protein (Chan et al., 1999). It
shows better gastric safety and control of peptic ulceration than the
ﬁrst generation of NSAIDs (Chakraborti et al., 2010). Unfortunately,
this drug was withdrawn from the market in 2004 because it likely
causes an imbalance of blood coagulation and thus increases the risk
of cardiovascular events (Arellano, 2005). In this study, rofecoxib was
predicted to target 842 non-redundant putative proteins, including its
potential therapeutic target COX2. The target number of rofecoxib is
the most in the selected six analgesics, which may partially answer for
its relatively high toxicity.
The common off-targets of analgesic-induced SADRs
In this study, three SADRs were chosen as examples for mechanism
study, and the numbers of their corresponding common off-targets
were given in Table 3. For all six analgesics, 182 distinct off-targets
were identiﬁed. Some of these 182 targets may answer for the common
SADRs like CDs; and some were likely linked with other ADRs common
to six analgesics. In the cases of cardiac arrhythmias and lung disorders,
331 and 557 common off-targets were identiﬁed respectively, including
the 182 common off-targets. It should be noted that these common off-
targets may be all related to CDs, CAs and LDs; however, only part of
them were likely associated with these SADRs.
The ADR-associated proteins (ADRAPs)
In total, 88 distinct putative ADRAPswere identiﬁed in this study, in-
cluding 53, 28, and 26 ADRAPs for CDs, CAs, and LDs respectively. The
full list of the putative ADRAPs was given in the Supplementary
Table 2S. It was observed that some ADRAPs were associated with mul-
tiple ADRs. For example, glutathione S-transferase P (GSTP1) and
glucose-6-phosphate isomerase (GPI) were identiﬁed as putative
Table 3
The common targets of analgesics, grouped by the severe adverse drug reactions (SADRs).
SADRs Analgesics Number of common targets
Cardiac disorders Oxycodone 182
Fentanyl
Morphine
Acetaminophen
Acetaminophen–hydrocodone
Rofecoxib
Cardiac arrhythmias Oxycodone 331
Fentanyl
Lung disorders Oxycodone 557
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target these common ADRAPs, concurrency of ADRs may happen.
CDs-associated proteins
Among the 53 putative ADRAPs for CDs, seven predicted targets, re-
ceptor tyrosine-protein kinase ErbB-2 (or MLN19) (Rajagopalan et al.,
2008), ErbB-3 (Camprecios et al., 2011), Sos-1 (Rauen, 1993), GTPase
HRas (Ha-Ras) (Castellano and Santos, 2011), cNos (Zhang et al.,
2012), angiotensin-converting enzyme ACE (Friedrich et al., 1994) and
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) (Eisenreich and
Rauch, 2011), were previously reported to be linked with cardiac
diseases. In addition, eight out of these 53 putative CDs-associated
targets, prothrombin (F2), AP-2 complex subunit beta (AP105B), beta-
2-microglobulin (B2M), alcohol dehydrogenase 1A (ADH1A), alpha-
aminoadipic semialdehyde dehydrogenase (ATQ1), glutathione
S-transferase P (GSTP1), retinoic acid receptor RXR-alpha (RXRA) and
matrix metalloproteinase-9 (MMP-9), were previously reported to be
ADRAPs of venous thrombosis, hyperlipidemia, sedation and dyspnea,
which were found to be the risk factors or complications of cardiac dis-
orders (Ageno et al., 2008; Goode et al., 1995; Sanborn et al., 2005).
Moreover, it was found that 10 predicted CDs-associated proteins
were involved in sugar metabolism or glycolysis, and 17 distinct
ADRAPs were involved in tumorgenesis (Supplementary Table 3S).
CAs-associated proteins
Of the 28 putative CAs-associated targets, eight were previously
found CAs-associated. They were phospholipase A2 (PLA2) (Gill and
Pulido, 2001; Woerman and Mendelowitz, 2013), rho-associated kinase
(ROCK) (Rikitake et al., 2005), mitogen-activated protein kinase kinase 1
(MKK1) (Rauen, 1993), GTPase HRas (Ha-Ras) (Estep et al., 2006), cell
division control protein 42 homolog (CDC42) (Qian et al., 2011), Sos-1
(Rauen, 1993), ras-related C3 botulinum toxin substrate (Rac) (Qian
et al., 2011) and serine/threonine-protein kinase B-raf (BRAF) (Rauen,
1993). Besides, ﬁve putative ADRAPs, ErbB-2, ErbB-3, PI3K, HBGF-1 and
cNOS, were also recognized as CDs-associated proteins with experimen-
tal evidences. In addition, ﬁve proteins out of the 28 putative CA-
associated proteins, angiotensin-converting enzyme 2 (ACEH), carbonic
anhydrase 2 (CAC), RAC-beta serine/threonine-protein kinase (PKB
beta), neprilysin (CALLA) and prothrombin (F2), were previously found
to be associated with ADRs like proteinuria and venous thrombosis.
LDs-associated proteins
Of the 26 putative targets, four proteins, glutathione peroxidase
(GPx-1), glutathione synthetase (GSH-S), glutathione S-transferase P
(GSTP1), and ornithine decarboxylase (ODC) were literature-reported
LDs-associated proteins (Breton et al., 2011; Cohen and Verma, 1989;
Duong et al., 2010; Rodriguez et al., 2005).Moreover, glutathione reduc-
tase (GR) and superoxide dismutases (SOD1, SOD2)were previously re-
ported to be associatedwith hyperoxic-induced lung toxicity (Folz et al.,
1999) in amechanism of reducing antioxidant ability (Gore et al., 2010).
Besides, eight literature-reported ADRAPs, AP-2 complex subunit beta
(AP105B), cAMP-dependent protein kinase catalytic subunit alpha(PKA C-alpha), caspase-3 (CASP-3), dual speciﬁcity mitogen-activated
protein kinase kinase 1 (MKK1), epoxide hydrolase 2 (CEH), mitogen-
activated protein kinase 14 (MAPK 14), peroxiredoxin-5, mitochondrial
(AOEB166) and Ras-related C3 botulinum toxin substrate 1 (Rac), were
on the list. However, they were linked with other ADRs such as cardiac
disorders.
The ADR–pathway associations
Among the 65 distinct ADRs induced by the six analgesics (Supple-
mentary Table 1S), only 29 were found to be associated with 89
literature-reported ADRAPs and 150 distinct KEGG pathways. Based
on these 29 ADRs, a network of 416 ADR-pathway associations was
built (Fig. 1). A statistical analysis indicated that 65% of 29 ADRs con-
nected with more than ﬁve pathways, approximately 28% of ADRs con-
nected with two to ﬁve pathways, and only approximately 7% of ADRs
connected with only one pathway. These results suggested that most
ADRs were the integrated results of disturbing multiple physiological
processes. On the other side, 89 (or about 59%) out of 150 distinct cellu-
lar pathways were found to mediate more than one ADR. This may ex-
plain, to some extent, why some ADRs appear together. To aid better
understanding of concurrency of ADRs, ADRAP–pathway connection
maps were constructed for CDs (Supplementary Fig. 1S), CAs (Supple-
mentary Fig. 2S) and LDs (Supplementary Fig. 3S), which involved
24 (53), 9 (28), and 6 (26) pathways (ADRAPs) respectively. It
looked that many of the associated pathways were connected via
ADRAPs. However, some pathways may play more dominant role
in analgesics-induced SADRs as they involved more ADRAPs than
others.
Further association analyses found that the impacts on SADRs
varied pathway by pathway (Supplementary Table 3S). Of the 24
CDs-associated pathways, base excision repair (hsa03410), sugar
metabolism (hsa00520, hsa00010, hsa00051), ErbB signaling pathway
(hsa04012), adherens junction (hsa04520), and antigen processing and
presentation (hsa04612) as well as various cancer pathways were
strongly associatedwith CDs. In similarway, regulation of actin cytoskel-
eton (hsa04810), cholinergic synapse (hsa04725) and pancreatic secre-
tion (hsa04972) were found to be strongly associated with CAs. In the
case of LDs, glutathione metabolism (hsa00480), pentose phosphate
pathway (hsa00030) and amyotrophic lateral sclerosis (hsa05014) had
comparatively strong associations.
Discussion
Off-targets suggest a shortcut for understanding idiosyncratic ADRs
Unlike the type A ADRs which are often dose-dependent and can be
studied in a way of on-target mechanism, Type B ADRs (or idiosyncratic
ADRs) are normally unpredictable. The unexpected bindings of drugs
with proteins other than their desired therapeutic targets (so-called
off-targets) are one of many potential factors that lead to adverse drug
events. In this study, a number of putative off-targets were identiﬁed
for analgesics-induced SADRs. These off-targets provide opportunity to
understand idiosyncratic ADRs in away of drug–target interactions. Gen-
erally, the severity of drug toxicitywas increasedwith the number of off-
targets; however, no consistent linear relations were observed. The pos-
sible add-on effects or even synergic actions of drug–target interactions
in a pathway may partially explain the SADRs (Supplementary Figs. 1S,
2S & 3S). Moreover, it would be a feasible route to link physiological
functions of ADRAPs (off-targets) for further ADR prediction.
The molecular mechanisms underlying analgesics-induced SADRs
Cardiac disorders
Cardiac disorders (CDs) sometimes occur during treatment with an-
algesics, especially coxibs like rofecoxib and valdecoxib. Cardiac disorder
Fig. 1. The ADR–pathway association network. The orange round rectangles, brown round rectangles, yellow diamonds, and light purple diamonds stand for cardiac disorders-related
ADRs, other ADRs, cardiac disorders-related pathways (their KEGG IDs) and other pathways, respectively. This network was constructed using the software Cytoscape with the yFiles Or-
ganic Layout algorithm, which covers 29 distinct ADRs, 150 KEGG pathways and 416 ADR–pathway associations.
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the heart. The induction of CDs is complicated because various factors,
e.g., oxidative stress, inﬂammatory cytokines, nitric oxide, endothelin,
and peptide growth factors, are all likely to be involved. However, most
current theories have not yet clearly illuminated the molecular basis
underlying drug-induced CDs. Some researchers proposed the altered
homeostatic theory, which states that the coxibs may induce cardiac
events by adding the risk of thrombosis/vasoconstriction (Hellstrom,
2007). There is another hypothesis that rofecoxib may increase the sus-
ceptibility of human low-density lipoprotein and cellular membrane
lipids to oxidative modiﬁcation, consequently resulting in cardiac prob-
lems (Mason et al., 2006). The adverse cardiac eventswere also acknowl-
edged to link with unsatisﬁed pharmacokinetics and over-exposure of
analgesics (Bjelland et al., 2013; Tegeder and Geisslinger, 2006). Never-
theless, it would be one of the possible mechanisms that analgesics in-
duce CDs via undesired interactions with a number of proteins and
cellular processes that play pilot role in cardiovascular system.
Upon the putative CDs-associated ADRAPs and pathways, it was con-
cluded that CDs were likely induced by a series of analgesics–target in-
teractions in ﬁve major routes (Fig. 2), and some of them were
partially supported by related studies: (1) Interference of ErbB signaling
pathway (Rajagopalan et al., 2008) by dysfunction of some key proteinssuch as ErbB-2, ErbB-3, SOS-1 and Ras in the pathway resulted in
dysfunction of MAPK signaling and eventually leading to SADRs (Wei
et al., 2011). (2) Dysfunction of PI3K or its upstreamproteins caused dys-
function of phosphatidyl inositol signaling, which also served as a meth-
od in studying pathogenesis of cardiovascular diseases (Eisenreich and
Rauch, 2011). (3) Abnormal ﬂux of Ca2+ by inhibition of ErbB-2, ErbB-
3, ACE and ADP-ribosyl cyclase 1 (CD38) or production of biological NO
catalyzed by cNos caused dysfunction of calcium signaling and undesired
muscle contraction, and eventually leaded to heart disease (Cartwright
et al., 2011; Dibb et al., 2007; Lehnart et al., 2009; Zhang et al., 2012).
(4) Dysfunction of proteins like DNA directed polymerases (POLB and
POLL), ATP-dependent DNA ligase I (LIG1) and DNA-3-methyladenine
glycosylase (ADPG) leaded to impairment of base excision repair
(BER), the predominant repair system against the oxidative DNA dam-
age, which were the causes of many diseases including various types of
CDs (Cooke et al., 2002; Siggens et al., 2012). (5) Dysfunction of proteins
like galactokinase (GALK1) and GPI resulted in impairment of glycogen
or sugar metabolism, which was a mechanism for diabetes and was
closely associated with heart diseases (Davidson and Parkin, 2009;
Mebazaa et al., 2013).
In addition to these ﬁve routes, pathways like focal adhesion, gap
junction, adherens junction and renin–angiotensin system (RAS) were
Fig. 2. Themechanism diagram of analgesic-induced cardiac disorders. Generally, the cardiac disorders could be induced by drug interference of ﬁve possible routes: base excision repair,
glycolysis, ErbB signaling, phosphatidyl inositol signaling and calcium signaling pathways.
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waysmay not directlymediate analgesic-induced CDs, but they are con-
nected to some extentwith the above ﬁve pivot pathways viamolecular
interactions (Fig. 2). Actions on them still have a chance to eventually
cause cardiac disorders. For instance, many evidences have suggested
that RAS may play a major role in the development and progression of
cardiovascular diseases by promoting vasoconstriction, sodium reab-
sorption, cardiac remodeling, norepinephrine release, and other poten-
tially detrimental effects (Doolan et al., 2004; Friedrich et al., 1994;
Humma and Terra, 2002; Sudano et al., 2010). It was interesting, how-
ever not surprising, that some cancer pathways were found strongly
associated with CDs. The fundamental cellular pathways like ErbB sig-
naling and glycolysis common to CDs and cancers may serve as good
explanations.Cardiac arrhythmias
Cardiac arrhythmias (CAs) were sometimes observed in patients un-
dergoing oxycodone and fentanyl treatment. Itwas noticed that 14 out of
the 28 putative CAs-associated targets were also predicted to be CDs-
associated. And as a subset of cardiac disorders, some factors that lead
to CDs were also associated with CAs. For instance, Ras, SOS, and PI3K
in the ErbB signaling pathwaywere detected for both CDs and CAs (Sup-
plementary Table 2S). Actually, the ErbB signaling is one of the funda-
mental cellular processes that are involved in many pathogenesis and
tumorgenesis processes (Supplementary Table 3S). On the other hand,
some factors that affected the normal functioning of actin in muscle
contraction, cell motility, cell signaling, cell junctions and cell shape
were considered likely the particular causes of cardiac arrhythmias
(Mezzano and Sheikh, 2012).
In summary, analgesics likely induced CAs in following ﬁve routes
(Fig. 3): (1) Undesired interactions with proteins like Asef, Cdc42, MSN,
PI3K, Rac, Raf, Ras, ROCK, and SOS-1 involved in the processes of actin sta-
bilization, local adhesion assembly and adherens junctions caused dys-
functions of cytoskeleton regulation of cardiac myocytes (Cunha andMohler, 2008). (2) Inhibition of ROCK, F2, or other key proteins in the
RAF-MEK-ERK signaling causeddysfunction of actomyosin assembly con-
traction and later cardiac arrhythmias (Rose et al., 2010). (3) Inhibition of
Cdc42, Rac or their upstream proteins caused dysfunction of MAPK sig-
naling (Qian et al., 2011). This also served as a common mechanism in
CDs. (4) Impairment of ion intake by inhibiting proteins like tyrosine-
protein kinase (JAK2), PI3K, and RAC-beta serine/threonine-protein
kinase (PKB beta) resulted in ion regulation problem in cholinergic syn-
apse and thus caused heart failure (Grant, 2009; Heist and Ruskin,
2010). (5) Inhibition of proteins like PLA2 andCD38 caused aberrant pan-
creatic secretion and resulted in blood glucose-lowering effects, which
was likely induced cardiac problems (Kim and Egan, 2008; Mebazaa
et al., 2013). Besides, pathways like protein digestion and absorption
and glutamatergic synapse can more or less be connected to these ﬁve
routes and associated with CAs.Lung disorders
Lung disorders (LDs) are rare but fatal ADRs. Among the six selected
analgesics, only oxycodone was reported to induce lung disorders. Early
study has found that pulmonary drug toxicity was likely a common and
possible cause of acute and chronic lung diseases including various path-
ologic lesions, from diffuse alveolar damage to interstitial pneumonias
and angiopathies (Pietra, 1991). Oxygen free radicals caused oxidative in-
jury of the lungs was also reported (Wang et al., 2007). Moreover, phar-
macokinetics of oxycodone and its metabolite oxymorphone have been
investigated and their roles in lung disorders such as bronchopneumonia
and emphysema were identiﬁed (Darke et al., 2011; Shuey et al., 2007).
However, themolecularmechanisms underlying howoxycodone induces
lung disorders are still retained to further exploration.
In this study, it was proposed that LDs were likely caused in follow-
ing two routes (Fig. 4): (1) Interception of glutathione (GSH) biotrans-
formation by direct interaction with proteins like GR, IDH, GPx-1, ODC,
SPDSY, GSTA1 and GSTP1 caused decrease of GSH, thus weakened
lungs' ability in promptly clearing reactive oxygen species like free
Fig. 3. The mechanism diagram of analgesic-induced cardiac arrhythmias. Cardiac arrhythmias were likely induced by interference of actin cytoskeleton regulation, ion intake and pan-
creatic secretion.
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This route was partially supported by previous experiments on oxida-
tive injury of lungs (Wang et al., 2007). (2) Interference of pentose me-
tabolism via proteins including glucose-6-phosphate isomerase (GPI),
fructose-1,6-bisphosphatase 1 (FBPase 1) and fructose-bisphosphate al-
dolase A (ALDOA) caused abnormal glycolysis, which were associated
with a number of disorders including LDs (Fontanesi et al., 2003;
Mebazaa et al., 2013). It is an interesting ﬁnding that the LDs were
strongly associated with the amyotrophic lateral sclerosis (ALS), a de-
generativemotor neurone disease. This was agreed with the clinical ob-
servation that ALS was sometimes characterized as rapid development
of difﬁculty breathing.Concurrency of ADRs
It was observed that cardiac disorders, like many other ADRs, were
not isolated events (Fig. 1). They had connections with several other
ADRs such as hyperglycemia and respiratory depression. The cross-
talks between CDs and other ADRs were bridged by their common off-
targets or pathways (Fig. 1). This observation may, to some extent, ex-
plain the concurrency of ADRs. For instance, hyperglycemia shares
seven common pathways with cardiac disorders, which is consistent
with the ﬁnding that cardiovascular disease was a common complica-
tion of diabetes and the leading cause of death among diabetes patients
(Davidson and Parkin, 2009). Therefore, it would be a good point ofpenetration in ADR relation study via identiﬁcation of common off-
targets or pathways.
Advantages and limitations of the framework
The exploration of molecular mechanisms underlying idiosyncratic
SADRs is a difﬁcult problem because it always involves a large set of
unexpected proteins and cellular processes. The difﬁculty lies in identi-
fying the ADR-associated proteins (ADRAPs) and determining their re-
lations. In this study, a feasible solution was introduced for global
identiﬁcation of putative ADRAPs via computational algorithms like re-
verse docking along with literature validation. This approach offers an
opportunity to globally understand SADRs at the molecular level,
which has difﬁcult to achieve experimentally so far. It also helps to plau-
sibly explain the concurrency of ADRs. Such computational approach
provides amuch broader vision of toxicology than traditional molecular
approaches. It is worthy ofmention that all the component tools used in
the framework can be easily replaced by other tools of similar functions.
For example, the reverse docking software INVDOCK can be substituted
by freeware like TarFisDock, DOCK, and AutoDOCK with customized
scripts for large scale screening.
ADR is a complicated event that can be affected bymany factors. This
framework is especially useful for understanding SADRs induced via
off-target or idiosyncratic mechanisms, which were estimated to make
up less than 30% of total ADRs. However, the framework is powerless
to explain majority of ADRs caused by factors like over-dosage or poor
Fig. 4. The mechanism diagram of oxycodone-induced lung disorders. It was proposed that abnormal GSH biotransformation and pentose metabolism may lead to lung disorders.
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for ADRs induced via on-target mechanism weren't considered in this
study. The absorption, distribution, metabolism and excretion of drugs
haven't been fully studied as well; although, some active metabolites
of analgesics were also included in the drug–target interaction
prediction.
The framework itself is still far from perfectness. Its performance is
largely affected by several aspects: (1) The target screening was subject
to human protein structures available in the PDB database. As a comple-
mentary solution, the prediction was carried out against both mammal
and human structures. However, mammal and human homologs some-
times do not have similar drug binding afﬁnity. (2) The INVDOCK, like
most current docking algorithms, used a scoring system, e.g., free energy
simulation, to quantitatively evaluate correct ligand–receptor interaction
and predict their binding afﬁnity. Unfortunately, there is no a golden
standard for clear differentiation of weak drug-target bindings, which
will lead to false positives. Many of these weak drug-target interactions
may be “trivial” interactions that are unable to trigger apparent pharma-
cological effects alone due to their comparatively low binding afﬁnities
against natural substrates or low drug concentration in blood. However,
it was proposed that a low dose of a combination drug, e.g., oxycodone–
paracetamol, may boost their pharmacological activities in a synergistic
mechanism (Gatti et al., 2010). Because of this possibility, those so-
called “trivial” interactions may be signiﬁcant, and therefore they were
still retained in the study. (3) The physiological actions of drug-target
binding (agonism or antagonism) haven't been determined, which may
lead to absolute opposite results. (4) Moreover, limited experimental ev-
idences of protein–ADR relations also affected the proper illumination ofADR mechanisms. These shortcomings are hard to be completely solved
so far; but can be improved, to some extent, by incorporating additional
algorithms like association analysis in this study.
Nevertheless, our approach and ﬁndingsmay offer experimental sci-
entists some good starting points in their attempts to mechanistically
explore or countermine SADRs. Furthermore, it showed that someputa-
tive targets of analgesics are known therapeutic targets of current
marketing drugs (Supplementary Table 2S). This may inspire further
applications of this method in drug repurposing.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.taap.2013.10.017.
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